ivermectin
FDA Approved, EMA Approved
Description
Ivermectin is a broad-spectrum antiparasitic agent that acts by binding to glutamate-gated chloride channels in invertebrate nerve and muscle cells. It is effective against various parasitic infections including filarial nematodes. Dirofilariasis, caused by Dirofilaria species, can be treated with ivermectin in combination with other antiparasitic therapies.
Indications & Therapeutic Use
Onchocerciasis, strongyloidiasis, scabies, pediculosis, dirofilariasis
Linked Diseases:
dirofilariasis
D004184
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
ivermectin
| Generic Name | ivermectin |
| Brands | 1 brand available |
| Active Ingredient | ivermectin |
| Drug Class | Onchocerciasis |
| Manufacturer | Merck & Co. |
| Dosage Forms | Oral tablet 3mg, 6mg, 12mg |
| Medical Code | P02CF01 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved, EMA Approved |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes